
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE (VRDN)
WebsitePrice
Market cap
Next catalystExpected Q4 2026VRDN-292 — planned Phase 1 in Graves’ disease · Trial initiationCompany presentation ↗
Cash
Chart & Events
Core Clinical
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
PreINDP2P3FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved / commercial
History / paused
VRDN PR & News
PR & News
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE